

Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone

The phase III PERSEUS trial compared daratumumab (dara), bortezomib (bor), lenalidomide (len), and dexamethasone (DVRd) to bor, len and dexamethasone (VRd) in newly diagnosed multiple myeloma (NDMM) patients that were autologous stem cell transplant (ASCT) eligible and demonstrated unprecedented complete response rates, minimal residual disease negativity (MRD-) rates, and progression-free survival (PFS) favoring DVRd over VRd.¹ The PERSEUS trial included twice weekly bor administration, DVRd consolidation for two cycles after ASCT, and dual agent post-ASCT maintenance with dara and len (DR). Little is known about the efficacy and administration patterns of DVRd in real-world (RW) practice including subsequent treatment after progression on DVRd. In this retrospective analysis, we aim to evaluate the RW efficacy and the clinical outcomes of NDMM patients treated with DVRd across the tri-site Mayo Clinic Comprehensive Cancer Center (MCCC). We retrospectively analyzed the medical records of patients treated with DVRd between June 2018 and June 2024 at the MCCC. Descriptive statistics were used to describe patient characteristics. Categorical variables were compared with χ^2 tests and continuous variables were compared with t tests. Outcomes were estimated using the Kaplan-Meier method. International Myeloma Working Group (IMWG) criteria was used for response assessment and MRD was evaluated with a minimum sensitivity of 1 in 10^5 nucleated cells or higher as per IMWG criteria.² Ultra high-risk (HR) myeloma was defined as per the new IMS/IMWG consensus recommendation.³ The study protocol and all amendments were reviewed and approved by the Institutional Review Board (IRB) at Mayo Clinic Florida (IRB # 23-001194) as an IRB-exempt study. The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki.

Four hundred and sixty-four patients were included; baseline characteristics are shown in *Online Supplementary Table S1*. Starting len dose was 25 mg in 356 (76.7%) patients, 15 mg in 40 patients (8.6%) and ≤ 10 mg in 65 patients (14.0%). Three hundred and ninety-nine (86%) patients received bor 1x per week and 63 (14%) 2x per week, 91 patients received one to two cycles of a different regimen prior to DVRd due to hospitalization (N=23), renal insufficiency (N=38), poor performance status (N=6), other (N=34). 315 (67.9%) patients underwent ASCT. The median number of induction cycles was five; four (range, 1-16) for patients who underwent ASCT and six (range, 1-28) for patients who did not. Forty-two

patients (13%) received post-ASCT consolidation with DVRd for a median of two cycles. Two-hundred and eighty-one patients received post-ASCT maintenance including 107 (38%) len, 53 (19%) bor-len, 91 (32%) dara-len, 14 (5%) dara, 16 (6%) other. The median follow-up time for all patients was 26 months (mo) (range, 17-39). The overall response rate (ORR) and MRD- rate (after induction) for patients who received once-weekly bor was 94% and 24%, compared to 94% and 27% for patients who received 2x weekly bor ($P=0.85$; $P=0.93$). Patients that received 2x weekly bor were not more likely to have RI ($P=0.16$).

The best ORR to induction for patients who underwent ASCT was 98% with 247 (79%) achieving $\geq$ very good partial response (VGPR), and 82 of 231 (36%) achieving MRD- in the bone marrow. Ninety-six percent of ASCT patients received melphalan 200 mg/m² and the ORR at day 100 was 97% with 63% (174/276 evaluated) achieving MRD-. At 1-year post-ASCT, 72% (93/109) were MRD-. The median PFS was not reached (NR) (Figure 1A). For patients who underwent ASCT, the PFS at 24 mo for patients who did not have HR fluorescence *in situ* hybridization (FISH) was 96% (range, 90-100%) compared to 92% (range, 86-98%) for patients with HR FISH and 83% (76-91%) for patients with ultra-HR FISH ($P=0.039$) (Figure 1B). The PFS at 24 mo for patients with RI who underwent ASCT was 94% (range, 86-100%) compared to 90% (range, 86-94%) for those without RI; $P=0.57$. The PFS at 24 mo for patients who received post-ASCT len maintenance was 93% *versus* 90% for patients who received dual agent maintenance (dara-len or bor-len) ($P=0.25$), although patients who got dual agent maintenance were more likely to have HR FISH than patients who received len maintenance ($P<0.001$). For patients with HR FISH, PFS at 24 mo with dara-len maintenance was 90.4% compared to 86.5% for bor-len maintenance ($P=0.60$). The PFS at 24 mo for patients that received post-ASCT consolidation was 91% compared to 85% for those that did not ($P=0.53$); patients who got post-ASCT consolidation were more likely to have HR FISH ($P=0.07$) and were more likely to be MRD+ (overall response [OR]=2.99; $P=0.091$). For patients that underwent ASCT, the 3-year PFS rate was 85% and the 3-year OS rate was 96% (Figure 1A) and those that achieved MRD- at anytime had a median PFS that was NR compared to 53 mo (range, 26-NR) for patients that did not achieve MRD- ($P<0.001$) (Figure 1D). Fifty-five patients had functional HR (FHR) MM (relapse within 18 mo of front-line therapy) and the median PFS for FHR patients who underwent ASCT was 15 mo (range, 11-NR), while median

PFS was NR for patients without FHR MM ($P<0.001$). The best ORR for patients who did not undergo ASCT was 87% and 30 of 85 (35%) evaluated achieved MRD- at any time. The median PFS was 57 mo (range, 52-NA) (Figure 1C) for patients who did not undergo ASCT. The PFS at 24 mo of patients with RI who did not undergo ASCT was 53% (range, 28-100%) compared to 64% (range, 55-75%) for those without RI; $P=0.42$. For patients that did not undergo ASCT, the 3-year PFS rate is 60% and the 3-year OS rate is 85% (Figure 1D).

Seventy-nine patients relapsed after the first-line DVRd. The most common second-line therapies were clinical trial (N=3), dara-carfilzomib (K)-d (N=7), dara-pomalidomide(P)-d (N=7), KPd (N=15), and other (N=41). The median follow-up time from second-line therapy was 10 mo, the best ORR to second-line therapy was 76%, and the median PFS

with second-line therapy was 18 mo (range, 7-NA) (Figure 1E). The most common second-line therapies for patients with FHR were DKD (N=5), KPD (N=11), other (N=33). For patients with FHR disease, at a median follow-up of 10 mo, the ORR was 61.8%, and the median PFS was 18 mo with second-line therapy.

In this RW analysis, the survival outcomes of NDMM patients treated with DVRd and ASCT were comparable to that reported in the PERSEUS trial. In PERSEUS, the PFS rate at 3 years was around 95% and the OS rate was around 96%¹ whereas in our RW study the 3-year PFS and OS rates were 85% and 96%, respectively. Efficacy was comparable between PERSEUS and our study as the ORR to DVRd induction in PERSEUS was 96.6% (95.2% $\geq$ VGPR)¹ and was 98% (79% $\geq$ VGPR) in our study. The PFS rate at 24 mo for patients with HR FISH (including 1q abnormalities) was




Figure 1. Survival outcomes. (A) Progression-free survival (PFS) and overall survival (OS) of patients treated with daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) who underwent autologous stem cell transplant (ASCT). (B) PFS based on standard-risk *versus* high-risk disease. (C) PFS and OS of patients treated with DVRd who did not undergo ASCT. (D) PFS of DVRd-treated patients who underwent ASCT based on minimal residual disease negativity (MRD-) status at anytime. (E) PFS of patients who progressed after front-line DVRd and were treated with second-line therapy.

similar between our study (92%) and PERSEUS (around 90%).⁴ The majority of the patients in our study got once weekly bor (86%) and there were no differences in ORR or MRD- rates after induction in patients treated with DVRd and ASCT who got once *versus* twice weekly bor. This is in line with clinical practice in the US where the majority of physicians use once weekly bor.^{5,6} Post-ASCT consolidation was only used in 13% (N=42) of patients in our study yet PFS at 3 years were similar to PERSEUS.

It is difficult to draw conclusions about the benefit of dual-agent maintenance in our study as those who received dual-agent maintenance were more likely to have HR cytogenetics. Nonetheless, amongst HR FISH patients, the PFS was similar whether patients received dara-len or bor-len maintenance which speaks to the previously reported efficacy of these maintenance regimens in PERSEUS (dara-len) and in other RW studies with bor-len.^{1,7} The PERSEUS study was not designed to evaluate the benefit of adding dara to len in the maintenance setting. The AURIGA trial demonstrated a PFS and MRD- benefit for dara-len compared to len maintenance albeit all patients were dara naïve in this trial.⁸ The ongoing SWOG1803 study (*clinicaltrials.gov. Identifier: NCT04071457*) will be able to evaluate the benefit of adding dara to len in the maintenance setting in dara-exposed patients.

Thirty-two percent (N=149) of patients in our study did not undergo ASCT and their 3-year PFS rate was 60% and 3-year OS rate was 85%. These survival outcomes are comparable albeit PFS was lower compared to patients treated with DVRd in the CEPHEUS trial (3-year PFS about 80% and 3-year OS 90%) that did not undergo ASCT.⁹

Limitations of our study include its retrospective design, the relatively short follow-up, and the heterogenous patient population. Although there was heterogeneity in institutional practices for dosing of DVRd and use of consolidation and dual agent maintenance, this analysis is reflective of the variability seen in RW practice patterns. While long-term PFS modeling from the PERSEUS trial predicts a median PFS of 17 years for patients treated with the PERSEUS regimen,¹⁰ RW data will be important to evaluate how PFS in the RW compares to PERSEUS especially if consolidation and post-ASCT maintenance strategies differ from those used in PERSEUS. The results of this RW study support the efficacy of induction with DVRd +/- ASCT in patients with NDMM.

Authors

Ricardo D. Parrondo,^{1*} Ricardo de Menezes,^{1,2*} Hanna Sledge,³ Madhavi Nayyar,¹ Kanika Yadav,¹ Leif Bergsagel,⁴ Rafael Fonseca,⁴ Prashant Kapoor,⁵ Francis Buadi,⁵ Morie A. Gertz,⁵ Angela Dispenzieri,⁵ Vivek Roy,¹ Taimur Sher,¹ Moritz Binder,⁵ Nadine Abdallah,⁵ Saurabh Chhabra,⁴ S. Vincent Rajkumar,⁵ Wilson I. Gonsalves,⁵ Joselle Cook,⁵ David Dingli,⁵ Yi Lin,⁵ Andre Fernandez,¹

Caitlin Flott,¹ Udit Yadav,⁴ Rahma M. Warsame,⁵ Erin E. Wiedmeier-Nutor,⁴ Taxiarchis Kourelis,⁵ Nelson Leung,⁵ Mustaqeem A. Siddiqui,⁵ Shaji Kumar,⁵ Asher A. Chanan-Khan¹ and Sikander Ailawadhi¹

¹Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL USA; ²Department of Hematology, Hospital Moinhos de Vento, Porto Alegre, Brazil; ³Division of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA; ⁴Division of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA and ⁵Division of Hematology, Mayo Clinic, Rochester, MN, USA

*RDP and RdM contributed equally as first authors.

Correspondence:

R.D. PARRONDO - Parrondo.Ricardo@mayo.edu

<https://doi.org/10.3324/haematol.2025.300401>

Received: December 21, 2025.

Accepted: February 23, 2026.

Early view: March 5, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Disclosures

RDP serves on the advisory board for Sanofi Aventis, Johnson and Johnson, Bristol Myers Squibb, and Astra Zeneca; and has received research funding from Bristol Myers Squibb Foundation, BeOne Medicines USA, and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen, and Takeda; and has received research funding from Pharmacyclics, Cellestar, and Janssen. LB served as consultant for Oncoceptidfes. Salaris, Radmetrix, Omeros, CellCentric, AbbVie, and Pfizer. SC honoraria from Sanofi, Ascentage Pharma, Sobi, Legend Biotech, and BMS; and research funding from Johnson & Johnson, Cynata Therapeutics, C4 Therapeutics, Abbvie, Ascentage Pharma, AstraZeneca, and Cullinan Therapeutics. AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage, and Millennium. PK received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen; and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals; and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. RF performs consulting for AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, and Sanofi; is part of the scientific advisory board of Caris Life Sciences; is on the board of directors of Antengene; and owns a patent for FISH in MM. SK discloses consulting or advisory role at Takeda, Janssen Oncology, Genentech/Rocher, Abbvie, BMS/Celgene, Pfizer, Regeneron, Sanofi, and K36 Therapeutics; discloses travel, accomodation and expenses from Abbvie, and Pfizer; discloses research funding from Takeda, Abbvie, Novartis, Sanofi, Janssen

Oncology, MedImmune, Roche/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, and BMS/Celgene. NL serves on an advisory board for Takeda Pharmaceuticals. YL discloses an advisory board role for Janssen, Sanofi, BMS, Regeneron, Genentech, Tesserae, Legend, and NexT Therapeutics; serves on the steering committee for Janssen, and Kite/Gilead; discloses research funding from Janssen, and BMS; serves on the scientific advisory board for Nonimmune, and Caribou; and serves on safety monitor board for Pfizer. The remaining authors have no conflicts of interests to disclose.

References

1. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2024;390(4):301-313.
2. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. 2016;17(8):e328-e346.
3. Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. *J Clin Oncol*. 2025;43(24):2739-2751.
4. Dimopoulos MA, Sonneveld P, Rodriguez-Otero P, et al. Daratumumab (DARA)/bortezomib/lenalidomide/dexamethasone (D-VRd) with D-R maintenance (Maint) in transplant-eligible (TE) newly diagnosed myeloma (NDMM): PERSEUS Cytogenetic Risk. *EHA Library*. 2024;421038:P974.
5. Banerjee R, Wang B, Anderson LD Jr, et al. Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. *Blood Cancer J*. 2023;13(1):162.
6. Cook J, Johnson I, Higgins A, et al. Outcomes with different administration schedules of bortezomib in bortezomib,

Contributions

RDP and RdM designed the study and wrote the manuscript. HS performed the statistical analysis. RdM, MN, and KY collected the data. All authors analyzed the data for the study, critically revised the manuscript and approved the final version.

Data-sharing statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restriction.

- lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. *Am J Hematol*. 2021;96(3):330-337.
7. Joseph NS, Kaufman JL, Gupta VA, et al. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumumab with RVD (DRVd) in transplant-eligible patients. *Blood Cancer J*. 2024;14(1):159.
8. Badros A, Foster L, Anderson LD Jr, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. *Blood*. 2025;145(3):300-310.
9. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. *Nat Med*. 2025;31(4):1195-1202.
10. Sonneveld P, Zweegman S, Facon T, et al. Modeling long-term progression-free survival in transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. *Haematologica*. 2025;110(S1):13.